Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Identifieur interne : 003B40 ( Ncbi/Merge ); précédent : 003B39; suivant : 003B41Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Auteurs : Erik Stroes [Pays-Bas] ; John R. Guyton [États-Unis] ; Norman Lepor [États-Unis] ; Fernando Civeira [Espagne] ; Daniel Gaudet [Canada] ; Gerald F. Watts [Australie] ; Marie T. Baccara-Dinet [France] ; Guillaume Lecorps [France] ; Garen Manvelian [États-Unis] ; Michel Farnier [France]Source :
- Journal of the American Heart Association [ 2047-9980 ] ; 2016.
Abstract
The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.
DOI: 10.1161/JAHA.116.003421
PubMed: 27625344
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001945
- to stream PubMed, to step Curation: 001921
- to stream PubMed, to step Checkpoint: 001921
Links to Exploration step
pubmed:27625344Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.</title><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands e.s.stroes@amc.uva.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><affiliation wicri:level="2"><nlm:affiliation>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills</wicri:cityArea></affiliation></author><author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza</wicri:regionArea><wicri:noRegion>Zaragoza</wicri:noRegion></affiliation></author><author><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name><affiliation wicri:level="1"><nlm:affiliation>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name><affiliation wicri:level="3"><nlm:affiliation>Sanofi, Clinical Development, R&D, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Clinical Development, R&D, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Chilly-Mazarin, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Chilly-Mazarin</wicri:regionArea><wicri:noRegion>Chilly-Mazarin</wicri:noRegion><wicri:noRegion>Chilly-Mazarin</wicri:noRegion></affiliation></author><author><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name><affiliation wicri:level="2"><nlm:affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Regeneron Pharmaceuticals Inc, Tarrytown</wicri:cityArea></affiliation></author><author><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name><affiliation wicri:level="3"><nlm:affiliation>Lipid Clinic, Point Médical, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lipid Clinic, Point Médical, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27625344</idno><idno type="pmid">27625344</idno><idno type="doi">10.1161/JAHA.116.003421</idno><idno type="wicri:Area/PubMed/Corpus">001945</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001945</idno><idno type="wicri:Area/PubMed/Curation">001921</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001921</idno><idno type="wicri:Area/PubMed/Checkpoint">001921</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001921</idno><idno type="wicri:Area/Ncbi/Merge">003B40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.</title><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands e.s.stroes@amc.uva.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><affiliation wicri:level="2"><nlm:affiliation>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills</wicri:cityArea></affiliation></author><author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza</wicri:regionArea><wicri:noRegion>Zaragoza</wicri:noRegion></affiliation></author><author><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name><affiliation wicri:level="1"><nlm:affiliation>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name><affiliation wicri:level="3"><nlm:affiliation>Sanofi, Clinical Development, R&D, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Clinical Development, R&D, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Chilly-Mazarin, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Chilly-Mazarin</wicri:regionArea><wicri:noRegion>Chilly-Mazarin</wicri:noRegion><wicri:noRegion>Chilly-Mazarin</wicri:noRegion></affiliation></author><author><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name><affiliation wicri:level="2"><nlm:affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Regeneron Pharmaceuticals Inc, Tarrytown</wicri:cityArea></affiliation></author><author><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name><affiliation wicri:level="3"><nlm:affiliation>Lipid Clinic, Point Médical, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lipid Clinic, Point Médical, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal of the American Heart Association</title><idno type="eISSN">2047-9980</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27625344</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>14</Day></DateCreated><DateRevised><Year>2017</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.116.003421</ELocationID><ELocationID EIdType="pii" ValidYN="Y">e003421</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Patients were randomly assigned to placebo, alirocumab 150 mg Q4W or 75 mg Q2W (calibrator arm), with dose adjustment to 150 mg Q2W at week (W) 12 if W8 predefined LDL-C target levels were not met. The primary efficacy endpoint was LDL-C percentage change from baseline to W24. Mean baseline LDL-C levels were 163.9 mg/dL (alirocumab 150 mg Q4W, n=59), 154.5 mg/dL (alirocumab 75 mg Q2W, n=116), and 158.5 mg/dL (placebo, n=58). In the alirocumab 150 mg Q4W and 75 mg Q2W groups (49.1% and 36.0% of patients received dose adjustment, respectively), least-squares mean LDL-C changes from baseline to W24 were -51.7% and -53.5%, respectively (placebo [+4.7%]; both groups P<0.0001 versus placebo). In total, 63.9% and 70.3% of alirocumab-treated patients achieved their LDL-C targets at W24. Treatment-emergent adverse events occurred in 77.6% (alirocumab 150 mg Q4W), 73.0% (alirocumab 75 mg Q2W), and 63.8% (placebo) of patients, with injection-site reactions among the most common treatment-emergent adverse events.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Alirocumab 150 mg Q4W can be considered in patients not on statin with inadequately controlled hypercholesterolemia as a convenient option for lowering LDL-C.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">URL: http://www.clinicaltrials.gov. Unique identifier: NCT02023879.</AbstractText><CopyrightInformation>© 2016 The Authors, Sanofi, and Regeneron Pharmaceuticals, Inc. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stroes</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands e.s.stroes@amc.uva.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guyton</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lepor</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Civeira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudet</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Gerald F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baccara-Dinet</LastName><ForeName>Marie T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Sanofi, Clinical Development, R&D, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecorps</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sanofi, Chilly-Mazarin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manvelian</LastName><ForeName>Garen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farnier</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lipid Clinic, Point Médical, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ODYSSEY CHOICE II Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02023879</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53</RefSource><PMID Version="1">22463922</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2014 Jun 17;63(23 ):2541-8</RefSource><PMID Version="1">24694531</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Jul 7;380(9836):29-36</RefSource><PMID Version="1">22633824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cardiol. 2014 Sep;176(1):55-61</RefSource><PMID Version="1">25037695</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2014 Mar 14;114(6):1022-36</RefSource><PMID Version="1">24625727</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2011 Jul;32(14):1769-818</RefSource><PMID Version="1">21712404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Lipidol. 2015 Nov-Dec;9(6):758-69</RefSource><PMID Version="1">26687696</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Heart Assoc. 2016 Jun 10;5(6):null</RefSource><PMID Version="1">27287699</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2015 May 14;36(19):1186-94</RefSource><PMID Version="1">25687353</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2006 Dec 19;114(25):2788-97</RefSource><PMID Version="1">17159064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9</RefSource><PMID Version="1">24842558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2015 Nov 14;36(43):2996-3003</RefSource><PMID Version="1">26330422</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934</RefSource><PMID Version="1">24239923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Apr 16;372(16):1489-99</RefSource><PMID Version="1">25773378</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2009 Jun 30;338:b2376</RefSource><PMID Version="1">19567909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Lipidol. 2014 Nov-Dec;8(6):554-61</RefSource><PMID Version="1">25499937</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Jul 6;360(9326):7-22</RefSource><PMID Version="1">12114036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2013 Apr 2;158(7):526-34</RefSource><PMID Version="1">23546564</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2015 Mar 10;313(10):1011-2</RefSource><PMID Version="1">25756433</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2004 Jul 13;110(2):227-39</RefSource><PMID Version="1">15249516</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2016 Nov;254:254-262</RefSource><PMID Version="1">27639753</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8</RefSource><PMID Version="1">26030325</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2012 May;33(9):1142-9</RefSource><PMID Version="1">22507979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Pharm Des. 2014;20(40):6314-24</RefSource><PMID Version="1">24953391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am Heart J. 2015 Jun;169(6):906-915.e13</RefSource><PMID Version="1">26027630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Nov 20;359(21):2195-207</RefSource><PMID Version="1">18997196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2015 May 1;36(17 ):1012-22</RefSource><PMID Version="1">25694464</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alirocumab</Keyword><Keyword MajorTopicYN="N">cardiovascular risk</Keyword><Keyword MajorTopicYN="N">low‐density lipoprotein cholesterol</Keyword><Keyword MajorTopicYN="N">placebo‐controlled</Keyword><Keyword MajorTopicYN="N">proprotein convertase subtilisin/kexin type 9</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Kostner</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Descamps</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gheyle</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathieu</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergeron</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girard</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoag</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hove</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeppesen</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kjærulf</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klarlund</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomsen</LastName><ForeName>K K</ForeName><Initials>KK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basart</LastName><ForeName>D C G</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kooy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liem</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swart</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troquay</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Het Hof-Wiersma</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viergever</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Visseren</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doughty</LastName><ForeName>R N</ForeName><Initials>RN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calvo</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Díaz-Díaz</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuentes</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gil-Extremera</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jericó</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matas Pericas</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mediavilla Garcia</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bolster</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koren</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>El Shahawy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zuzarte</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Jennifer G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rader</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cannon</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colhoun</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kastelein</LastName><ForeName>John J P</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huo</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olsson</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waters</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larrey</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patriarca</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molenberghs</LastName><ForeName>Geert</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tricoci</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahaffey</LastName><ForeName>Kenneth W</ForeName><Initials>KW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopes</LastName><ForeName>Renato D</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Bimal R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>Rajendra H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roe</LastName><ForeName>Matthew T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eapen</LastName><ForeName>Zubin</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armaganijan</LastName><ForeName>Luciana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertolami</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leonardi</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolls</LastName><ForeName>Bradley J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jordan</LastName><ForeName>J Dedrick</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducrocq</LastName><ForeName>Grégory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puymirat</LastName><ForeName>Etienne</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27625344</ArticleId><ArticleId IdType="pii">JAHA.116.003421</ArticleId><ArticleId IdType="doi">10.1161/JAHA.116.003421</ArticleId><ArticleId IdType="pmc">PMC5079013</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Bourgogne</li><li>Bourgogne-Franche-Comté</li><li>Californie</li><li>Caroline du Nord</li><li>Hollande-Septentrionale</li><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li><li>État de New York</li></region><settlement><li>Amsterdam</li><li>Dijon</li><li>Montpellier</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name></region></country><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name></region><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name></country><country name="Espagne"><noRegion><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name></noRegion></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name></region><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003B40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27625344
|texte= Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27625344" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |